Response Genetics EBIT

Response Genetics (RGDXQ) currently reports a EBIT of $-13M as of March 2015. That compares with $-10M in the prior-year period — down 26.5% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Response Genetics's EBIT history and peer comparisons.

Response Genetics's EBIT decreased from $-10M to $-13M — a 26.5% year-over-year decrease (period ending March 2015). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Response Genetics's EBIT of $-13M is lower than the its sector sector average of $-6.4M. That is roughly 105.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Response Genetics reported $-13M in EBIT as of March 2015. That compares with $-10M in the prior-year period — down 26.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-13M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Response Genetics, and consider following RGDXQ for alerts when major investors trade the stock.